Pond GR - Search Results

1

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.

Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. Pond GR, et al. BJU Int. 2014 May;113(5b):E137-43. doi: 10.1111/bju.12564. BJU Int. 2014. PMID: 24219029

2

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.

Gomez-Abuin G, Winquist E, Stadler WM, Pond G, Degendorfer P, Wright J, Moore MJ. Gomez-Abuin G, et al. Invest New Drugs. 2007 Apr;25(2):181-5. doi: 10.1007/s10637-006-9009-4. Epub 2006 Sep 16. Invest New Drugs. 2007. PMID: 16983508 Clinical Trial.

3

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX. Elser C, et al. Among authors: pond gr. J Clin Oncol. 2007 Aug 20;25(24):3766-73. doi: 10.1200/JCO.2006.10.2871. J Clin Oncol. 2007. PMID: 17704426 Clinical Trial.

4

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF. Sonpavde G, et al. Among authors: pond gr. Urol Oncol. 2012 Sep;30(5):607-13. doi: 10.1016/j.urolonc.2010.07.002. Epub 2010 Oct 2. Urol Oncol. 2012. PMID: 20888271

5

The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. Sonpavde G, et al. Among authors: pond gr. Cancer. 2011 Sep 1;117(17):3963-71. doi: 10.1002/cncr.25982. Epub 2011 Mar 1. Cancer. 2011. PMID: 21365623 Free PMC article.

6

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.

Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Pond GR, et al. Eur Urol. 2012 Feb;61(2):363-9. doi: 10.1016/j.eururo.2011.06.034. Epub 2011 Jun 22. Eur Urol. 2012. PMID: 21715086 Free PMC article.

7

Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.

Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G. Pond GR, et al. BJU Int. 2012 Dec;110(11 Pt B):E461-8. doi: 10.1111/j.1464-410X.2012.11148.x. Epub 2012 Apr 23. BJU Int. 2012. PMID: 22520631 Clinical Trial.

8

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G. Pond GR, et al. Urol Oncol. 2013 Nov;31(8):1457-63. doi: 10.1016/j.urolonc.2012.02.008. Epub 2012 May 1. Urol Oncol. 2013. PMID: 22552048 Clinical Trial.

9

Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.

Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Pond GR, et al. Clin Genitourin Cancer. 2012 Dec;10(4):239-45. doi: 10.1016/j.clgc.2012.06.004. Epub 2012 Sep 19. Clin Genitourin Cancer. 2012. PMID: 23000202 Clinical Trial.

10

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Sonpavde G, et al. Among authors: pond gr. Eur Urol. 2013 Apr;63(4):717-23. doi: 10.1016/j.eururo.2012.11.042. Epub 2012 Nov 26. Eur Urol. 2013. PMID: 23206856 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page